Analysis Highlights Worldwide Prescription Drug Sales 2019-24 in figures CAGR* +6.9%2019-24 Drivers Brakes 62 New FDA NME approvals Sales at risk between 2019 and $198bn in 2018, up from 55 in 2017 2024 due to patent expiries Additional sales in 2024 Anti-rheumatics decline as -1.0% $109bn from orphan drugs vs. 2018 Humira, Enbrel and Remicade CAGR face competition 2018-24 Proportion of 2024 industry Clinical development spend per 19.4% sales from oncology therapies approval for cardiovascular drugs, $1bn ($237bn) the highest of any therapy area. Is the risk worth the reward? Number of FDA NME approvals R&D as a proportion of 431 anticipated from current prescription sales in 2024, 18.0% clinical pipeline down from 21.6% in 2018 * Compound Annual Growth Rate. • Prescription drug sales expected to reach $1.18trn in 2024. Immuno-oncology line extensions signi昀椀cantly contribute to growth; emergence of novel technologies such as cell and gene therapy mark an in昀氀ection point in pharma’s evolution • P昀椀zer will be the leading prescription drug company in 2024 with sales of $51.2bn, ahead of Novartis and Roche ® 5 EvaluatePharma World Preview 2019 Copyright © 2019 Evaluate Ltd. All rights reserved.